image

Product Candidates

We are focused on the rapid design and development of new medicines based on breakthroughs in cancer research.

We are committed to developing drugs that take a unique approach to precision oncology by focusing on broad mechanisms that have multiple links to oncogenic driver pathways in select patients.

Pipeline-Page-Graphic

We have developed a diverse pipeline consisting of six distinct programs spanning methyltransferases, kinases, protein-protein interactions, and targeted protein degraders. Our pipeline is geared towards serving patients with high unmet medical need where there are limited or no treatment options.

ProgramIndicationsDiscoveryIND EnablingPhase 1Phase 2Phase 3
PR-01
PRT543
(PRMT5)
Selected Solid Tumors (Incl. ACC, HRD+)

PRT543
(PRMT5)
Selected Myeloid Malignancies (Incl. MF & MDS)

PRT811
(Brain Pentrant PRMT5)
GBM & CNS Metastatic Cancers

PRT1419
(MCL1)
Selected Hematological Malignancies (oral formulation)

PRT1419
(MCL1)
Solid Tumors (IV formulation)

PRT2527
(CDK9)
Selected Solid & Hematological Malignancies

PRT-SCA2
(SMARCA2)
Multiple Genomically Selected Cancers

PRT-K4
(KINASE)
Solid Tumors

DrugIndicationStage
PR-01
PRT543
(PRMT5)
Selected Solid Tumors (Incl. ACC, HRD+)Phase 1
PRT543
(PRMT5)
Selected Myeloid Malignancies (Incl. MF & MDS)Phase 1
PRT811
(Brain Pentrant PRMT5)
GBM & CNS Metastatic Cancers Phase 1
PRT1419
(MCL1)
Selected Hematological Malignancies (oral formulation)IND Enabling
PRT1419
(MCL1)
Solid Tumors (IV formulation)IND Enabling
PRT2527
(CDK9)
Selected Solid & Hematological MalignanciesIND Enabling
PRT-SCA2
(SMARCA2)
Multiple Genomically Selected CancersDiscovery
PRT-K4
(KINASE)
Solid TumorsDiscovery